source
- Tango Therapeutics reports 82% tumor response in combo trial for advanced pancreatic cancerTango Therapeutics and Revolution Medicines presented data showing that their experimental combination therapy produced tumor responses in 82% of patients with a specific form of advanced pancreati…
- Alnylam to launch pivotal Huntington’s trial after early study shows strong huntingtin knockdownAlnylam Pharmaceuticals announced plans to move its Huntington’s disease RNAi therapy brezosiran into a pivotal, placebo‑controlled trial slated for 2027, pending regulatory alignment. The decisio…